Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bristol-Myers Squibb Co BMY

Healthcare
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule... see more

Recent & Breaking News (NYSE:BMY)

Bristol Myers Squibb to Participate in the Guggenheim Healthcare Talks 2023 Oncology Conference

Business Wire February 3, 2023

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022

Business Wire February 2, 2023

Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Adult Patients with Anemia-Associated, Non-Transfusion-Dependent (NTD) Beta Thalassemia

Business Wire January 27, 2023

Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis

Business Wire January 27, 2023

Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi® (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Business Wire January 26, 2023

The Robert A. Winn Diversity in Clinical Trials Award Program Established by the Bristol Myers Squibb Foundation to Expand with Amgen's Commitment of $8 Million

Business Wire January 19, 2023

Biking the Globe for C2C4C

Accesswire January 5, 2023

Bristol Myers Squibb to Present at J.P. Morgan's 41st Annual Healthcare Conference

Business Wire January 3, 2023

Bristol Myers Squibb Completes Sale of Manufacturing Facility in Syracuse, New York

Business Wire January 3, 2023

Bristol Myers Squibb to Report Results for Fourth Quarter 2022 on February 2, 2023

Business Wire December 15, 2022

Bristol Myers Squibb Announces First Disclosures and New Data at ASH 2022, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio

Business Wire December 12, 2022

Bristol Myers Squibb Announces Dividend Increase

Business Wire December 8, 2022

Envisagenics Announces Research Collaboration with Bristol Myers Squibb

PR Newswire November 29, 2022

Bristol Myers Squibb Data at ASH 2022 Highlight Innovative Therapeutic Platforms Across a Range of Blood Diseases

Business Wire November 21, 2022

Health Canada Approves Camzyos(TM) (mavacamten capsules) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Canada NewsWire November 10, 2022

Bristol Myers Squibb to Participate in the Wolfe Research Healthcare Conference

Business Wire November 9, 2022

Kura Oncology Announces Financing Transactions with Bristol Myers Squibb and Hercules Capital, Providing Access to up to $150 Million

GlobeNewswire November 3, 2022

Data Reinforcing Impact of Bristol Myers Squibb Cardiovascular Portfolio to be Presented at American Heart Association Scientific Sessions 2022

Business Wire November 2, 2022

Bristol Myers Squibb Announces Positive Topline Results of Phase 3 COMMANDS Trial

Business Wire October 31, 2022

Obsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb

PR Newswire October 27, 2022